OK. some pts 1) There was always the patent challenge risk so as long as that was out there doubt they could have got a good price post R-IT results . 2) John Thero believed AMRN could out grow the generics in the US and poured huge $ into trying to do it. Big mistake Many of us here argued against that at the time . We aren't going to win competing against generics .....concentrate on where we have patent protection 3 ) Look what Novartis has done to reinforce the perceived / documented benefits of Leqvio ....multiple trials conforming benefit . Follow up real world studies etc . Once Dr Nissen appeared trashing R-IT , AMRN needed independent confirming studies at least in small high risk populations. 4) The US operations are IMHO a weight around AMRN's neck due to their API supply agreements . Thats a factor in dissuading offers . AMRN probably faces significant penalties if they cancel those supply agreement . Current situation is they buy the API , sell the finished product in the US ...and make zero or little $
Market Data 
Markets 
AI
